R&D/Clinical Trials

Latest News

Carvykti Demonstrates Clinically Meaningful Improvement in Patients with Relapsed or Lenalidomide-Refractory Multiple Myeloma After One Line of Prior Therapy
Carvykti Demonstrates Clinically Meaningful Improvement in Patients with Relapsed or Lenalidomide-Refractory Multiple Myeloma After One Line of Prior Therapy

July 2nd 2024

Results of the Phase III CARTITUDE-4 study showed that treatment with Carvykti achieved a more significant improvement in overall survival (OS) compared to standard therapies.

Thomas Rademacher
Preparing for Outbreaks: Q&A with Thomas Rademacher, MD, PhD

June 26th 2024

Hugues Wallemacq, CEO of EXO Biologics.
EXO Biologics CEO Discusses Innovation in Developing Exosome Therapies

June 25th 2024

Shawn Davis, CEO of Liberate Bio.
Improving the Efficacy of Genetic Medicines

June 24th 2024

Dr. Emilio Emini
The Need for Not-For-Profit: Q&A with Dr. Emilio Emini

June 24th 2024

Video Interviews
Podcasts

More News